Table 2 Character of included studies (treatment)
Study [first author, publish year] | Country | Study design | Primordial therapy | Sample size (MSC/control) | Median age (MSC/control) | Male (%) (MSC/control) | Time of aGVHD diagnosis (mean days after HSCT) | aGVHD grade | MSC source | MSC dose | Number of MSC infusions | Median duration of GVHD prior to enrollment | Maximum follow-up (day) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Zhao K, 2015 [37] | China | nRCT | HSCT | 28/19 | 26/29 | 67.9%/63.2% | 37/33 | aGVHD: II-IV | Bone marrow | 1 × 106 cells/kg | Once a week (until patients got CR or received 8 doses of MSCs) | 17 (11–55) | 1312 |
Szabolcs P, 2010 [39] | Italy | RCT | HSCT | 14/14 | 7/10 | 50.0%/71.4% | NR | aGVHD: II-IV | Umbilical cord | 2 × 106 cells/kg | Once a week for 4 weeks (CR) or 8 weeks (PR) | 20/8 | 139 |
Remberger, M, 2012 [38] | Sweden | nRCT | HSCT | 15/13 | 57/48 | NR | 63/56 | aGVHD: III-IV | NR | 3 × 107 cells | NR | 8(0–37) | 730 |